1460774846-78a64da3-8e03-4c83-954e-45492b775e41

1. A method of diagnosing an inflammatory or ischaemic condition in a joint comprising:
providing a device having:
an emitter arranged to emit a beam of infrared light;
a collector arranged to collect and analyze reflected light, said collector for producing an infrared spectrum; and
a database containing a plurality of spectra previously collected from joints, said spectra being divided into at least two groups: spectra from joints diagnosed as having the inflammatory or ischaemic condition and spectra from nonafflicted joints;

providing a joint;
positioning the device proximal to the joint such that the emitter contacts the joint;
emitting a beam of near infrared light from the emitter into the joint;
collecting and analyzing reflected light from the beam, thereby producing a patient spectrum;
comparing the patient spectrum to the database spectra; and
assigning the patient spectra to a group, thereby diagnosing the joint.
2. The method according to claim 1 wherein the inflammatory or ischaemic condition is rheumatoid arthritis.
3. The method according to claim 1 wherein the patient spectrum is a mean spectrum of two or more spectra of the joint.
4. The method according to claim 1 wherein the patient spectrum is compared to the database spectra over wavelengths of high accuracy.
5. The method according to claim 4 wherein the wavelengths of high accuracy are selected from the group consisting of: wavelengths corresponding to oxyhemoglobin to deoxyhemoglobin ratio; wavelengths corresponding to reduced cytochrome aa3; wavelengths corresponding to oxidized cytochrome aa3; wavelengths corresponding to deoxyhemoglobin; wavelengths corresponding to oxyhemoglobin; wavelengths corresponding to cytochrome aa3; wavelengths corresponding to water; wavelengths corresponding to proteins; wavelengths corresponding to lipids; and combinations thereof.
6. The method according to claim 1 wherein the emitter is a fibre optic probe.
7. The method according to claim 2 wherein the database spectra are divided into three groups: control, early rheumatoid arthritis and late rheumatoid arthritis.
8. A device for diagnosing an inflammatory or ischaemic condition in a joint comprising:
an emitter arranged to emit a beam of infrared light;
a collector for producing an infrared spectrum from reflected infrared light; and
a database containing a plurality of prior spectra previously collected from joints, said spectra being divided into at least two groups:
spectra from joints diagnosed as having the inflammatory or ischaemic condition and spectra from nonafflicted joints; and
an analyzer for comparing the spectrum to the prior spectra and assigning the spectrum to a group, thereby diagnosing the joint.
9. The device according to claim 8 wherein the inflammatory or ischaemic condition is rheumatoid arthritis.
10. The device according to claim 8 wherein the collector produces a spectrum that is a mean spectrum comprised of two or more spectra of the joint.
11. The device according to claim 8 wherein analyzer analyzes the spectrum for wavelengths of high accuracy and compares the spectrum to the database spectra over the wavelengths of high accuracy.
12. The device according to claim 8 wherein the emitter is a fibre optic probe.
13. The method according to claim 9 wherein the spectra are divided into three groups: control, early rheumatoid arthritis and late rheumatoid arthritis.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A contrast agent represented in general formula I, and pharmaceutically acceptable salts, hydrates and solvents thereof:
wherein
BP is a bisphosphonate;
is a linker; and
is a metal chelate selected independently from:
2. The contrast agent of claim 1, wherein said bisphosphonate is independently selected from the group consisting of alendronate, etidronate, ibandronate, incadronate, neridronate, olpadronate, phosphonate, pamidronate, risedronate, tiludronate and zoledronate.
3. The contrast agent of claim 1, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.
4. The contrast agent of claim 1, wherein M is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.
5. A contrast agent represented in general formula II, and pharmaceutically acceptable salts, hydrates and solvents thereof:
wherein
BP is a bisphosphonate;
is a linker; and
M is Y, In, Gd, Eu, or a lanthanide.
6. The contrast agent of claim 5, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.
7. The contrast agent of claim 5, wherein said bisphosphonate is independently selected from the group consisting of alendronate, etidronate, ibandronate, incadronate, neridronate, olpadronate, phosphonate, pamidronate, risedronate, tiludronate and zoledronate.
8. A contrast agent having a formula selected from the group consisting of:
wherein
BP is a bisphosphonate;
is a linker; and
M is Y, In, Gd, Eu, or a lanthanide.
9. The contrast agent of claim 8, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.
10. The contrast agent of claim 8, wherein said contrast agent is in a form of pharmaceutically acceptable salts, hydrates and solvents.
11. The contrast agent of claim 8, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.
12. A method of making a contrast agent, said method comprising:
(a) providing an organic chelating ligand, wherein said organic chelating ligand selected from the group consisting of:
wherein
R is t-butyl ester, ester or hydrogen; and
R1 is
(b) reacting said organic chelating ligand with a linker, wherein said linker having a primary amine and a carboxylic moiety at opposing ends;
(c) treating said carboxylic moiety with oxalyl chloride under conditions capable of forming an acid chloride at said carboxylic moiety;
(d) reacting said acid chloride in one pot with trialkyl phosphite and dialkyl phosphite to form a alkylester protected bisphosphonate;
(e) deprotecting one or more carboxylic acid ester of said organic chelating ligand to yield one or more carboxylic acid functionality;
(f) chelating a metal ion to result in a metal chelate, wherein said linker separate said metal chelate and said alkylester protected bisphosphonate; and
(g) deprotecting one or more bisphosphonate ester of said alkylester protected bisphosphonate, wherein deprotection results in said contrast agent.
13. The method of claim 12, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.
14. The method of claim 12, wherein said metal ion is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.
15. A method of making a contrast agent, said method comprising:
(a) providing an organic chelating ligand, wherein said organic chelating ligand selected from the group consisting of:
wherein
R is t-butyl ester, ester or hydrogen; and
R1 is
(b) reacting said organic chelating ligand with a linker, wherein said linker having a primary amine and a carboxylic moiety at opposing ends;
(c) deprotecting one or more carboxylic acid ester of said organic chelating ligand to yield one or more carboxylic acid functionality;
(d) chelating a metal ion to result in a metal chelate, wherein said linker on said metal chelate having said carboxylic moiety; and
(e) reacting an amino bisphosphonate with said carboxylic moiety of said metal chelate under a condition capable of forming amide bond to results in said contrast agent.
16. The method of claim 15, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.
17. The method of claim 15, wherein said amino bisphosphonate is an amino alkylester protected bisphosphonate, wherein deprotection of one or more bisphosphonate ester results in said contrast agent.
18. The method of claim 15, wherein said metal ion is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.
19. A method of making a contrast agent, said method comprising:
(a) providing an organic chelating ligand, wherein said organic chelating ligand selected from the group consisting of:
wherein
R is t-butyl ester, ester or hydrogen; and

R1 is
(b) reacting an amino bisphosphonate with said organic chelating ligand under a condition capable of forming amide bond between said amino bisphosphonate and said organic chelating ligand;
(c) deprotecting one or more carboxylic acid ester of said organic chelating ligand to yield one or more carboxylic acid functionality; and
(d) chelating a metal ion to said one or more carboxylic acid ester of said organic chelating ligand to result in said contrast agent.
20. The method of claim 19, wherein a linker separates said organic chelating ligand and said amino bisphosphonate, wherein said amino bisphosphonate is independently selected from the group consisting of alendronate, neridronate, and pamidronate, wherein said linker is selected from the group consisting of amino acid, alkane, polyethylene glycol and polypropylene glycol.
21. The method of claim 19, wherein said metal ion is selected from the group consisting of Y, In, Gd, Eu and lanthanide, wherein Gd is chelated for magnetic resonance imaging, Eu is chelated for CEST imaging and Y is chelated for hyperpolarized imaging.